Semaglutide vs Retatrutide: Head-to-Head Comparison
Semaglutide is the most widely prescribed GLP-1 agonist with proven CV benefits and ~15% weight loss. Retatrutide is an investigational triple agonist showing 24.2% weight loss in Phase 2 — potentially the most effective obesity treatment ever tested. Semaglutide is available now; retatrutide remains in clinical trials.
Side-by-Side Comparison
| Dimension | Semaglutide | Retatrutide |
|---|---|---|
| Evidence Level | Level A — extensive Phase 3 data and real-world evidence | Level B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH) |
| FDA Status | Approved for T2D and obesity (multiple formulations) | Not approved; still in Phase 3 clinical trials |
| Weight Loss Efficacy | ~15% mean body weight loss (Wegovy 2.4 mg) | Up to 24.2% weight loss (12 mg dose, Phase 2) |
| Mechanism | GLP-1 receptor agonist only | Triple agonist: GIP + GLP-1 + glucagon receptors |
| Side Effects | Well-characterized GI side effects; manageable | Similar GI profile; long-term safety unknown |
| Cardiovascular Data | Proven 20% CV event reduction (SELECT trial) | No CV outcome data yet |
Peptide Overviews
Semaglutide
AFDA ApprovedSemaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.
Retatrutide
BHuman StudiesRetatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.
Semaglutide vs Retatrutide: FAQ
Stay Informed on Peptide Research
Get weekly comparison updates, new study alerts, and regulatory changes.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.